How Does WellDoc Improve Outcomes for Type 2 Diabetes Patients?

Read Transcript

So in diabetes the primary metric of wellness is A1C. In simple English it's the amount of sugar in your blood. It's volumetric percentage, the American Diabetes Association target is 7%, that means 7% of your blood volume of sugar. Now the importance of that number is as follows, every one point delta from seven to eight, eight to nine represents a 42% increase the risk of heart attacks, strokes, kidney failure, blindness, amputation.

A drug is held by the A1C if it drops A1C by half a point. So for example mark the block buster drug Genuvia, drops it by seven tenth of a point. WellDoc got a two point reduction in our clinical trials not once but many times people said what are they doing, swallowing the phone? We said no, they are doing what their doctors told them to do.

So we are seeing outcomes for patients that are two to three times better than the best of block buster drugs alone. And the sister statistics to that is physicians who actually got that consult that clinical decision support, were two to five times more likely to actually make a medication change.

The significance of that is as follows in the United States today. The average primary carried off weights 14 to 16 months before they add a new drug or titrated drug to a patients regimen in case of insulinazation/gt it's four to six years of delay. There's no blame here, it's a dangerous drug and patients got to be ready for it.

But in that 46 years, retinopathy setting in, neuropathy setting in, kidney damage is setting in, heart damage is setting in, so we have an opportunity to move that needle as well and prescribed side as well as the patient side.